Biosimilar EPO for anemia in low-risk MDS
Part of Blood & lymphatic clinical trials.
This trial tests how well a biosimilar version of erythropoietin (a drug that boosts red blood cells) works in people with low-risk myelodysplastic syndrome (MDS) who have anemia. It aims to see if this treatment can safely improve low hemoglobin levels without needing more intensive therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of myelodysplastic syndrome (MDS), which is a bone marrow disorder that can cause low blood counts.
- Your MDS must be considered lower-risk, meaning it has a low, very low, or intermediate IPSS-R score.
- Before starting treatment, your hemoglobin (red blood cell count) must have been less than 10 grams per deciliter (g/dL), showing signs of anemia.
- Your erythropoietin (EPO) level before treatment must have been less than 500 U/L. (EPO is a hormone that signals your body to make red blood cells.)
- You must have started treatment with a biosimilar form of erythropoietin alfa between June 2018 and December 2021 at the IRCCS hospital in Bologna.
- You are 18 years or older and willing to give consent.
- You do not have other serious health problems, such as severe immune system weakness (ECOG >3) or other causes of anemia (like chronic inflammation, internal bleeding, or a type of anemia called hemolysis).
- You are not currently receiving other cancer chemotherapy drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This trial compares three different medicines to see which works best for people with a blood condition called myelodysplasia (also called MDS) that causes anemia. It aims to find the safest and most effective option to improve blood counts and reduce symptoms like tiredness or shortness of breath.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
Hear when a new Myelodysplastic Syndromes (MDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.